To Assess the Safety and Tolerability of Intranasal Administration of a Male Donor Memory T Lymphocyte Solution
Conditions
Brief summary
Proof-of-concept trial to assess the safety and tolerability of intranasal administration of a male donor memory T lymphocyte solution in females aged between 18 - 55 years of age.
Interventions
OTHERCD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.
CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.
Sponsors
Cristina Calvo Rey
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Standard 3+3 dose escalation design to determine the optimal dosage of the investigational product, consisting of CD45RA- memory T lymphocytes, for intranasal administration in healthy female volunteers. The dose escalation will be based on the observed occurrence of dose-limiting toxicities (DLTs).
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Female subjects between 18 - 55 years of age. * Participants are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Patients with the ability to comprehend and sign the informed consent. * Written informed consent obtained prior to any screening procedures. * Subjects in good health with no baseline disease of any kind.
Exclusion criteria
* Participants are not willing or able to comply with either: all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, or other study procedures. * Participants who are currently under medical follow-up for any medical condition or who are regularly taking medication for any condition. * Subject has experienced symptoms consistent with a respiratory infection within the 7 days prior to the administration of the investigational treatment. * Have a known history of human immunodeficiency virus infection, Hepatitis B or Hepatitis C; testing is not required in the absence of prior documentation or known history. * Have a known history of drug substance abuse. * Pregnant or breastfeeding women, where pregnancy is defined as the state of a female after conception and until the termination of gestation. * Any other condition that, in the opinion if the Investigator, may interfere with the efficacy and/or safety evaluation of the trial. * Any condition or situation precluding or interfering with the compliance with the protocol. * Participant is currently enrolled or has enrolled in a clinical trial three months prior to inclusion in the current study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability | 6 months | Safety and tolerability will be evaluated based on the frequency and attribute of DLT (dose limiting toxicities) in the first 7 days after solution administration and the incidence of all AEs and serious adverse events (SAEs) during study period. The primary endpoint will be DLT, defined as any grade 3 or higher adverse event (as defined in the Common Terminology Criteria for Adverse Events (CTCAE) version 5) with an attribution of definitely or probably related to the product administration. The highest dose found safe in the present study will be determined as the maximum tolerated dose (MTD). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Persistence of donor cells in the nasal mucosa of participants post-administration of treatment cells | 6 months | Persistence of donor cells in the nasal mucosa of participants post-administration of treatment cells, confirmed by the detection of male donor cells through nasopharyngeal aspirate and the presence of a Y chromosome. |
Countries
Spain
Outcome results
None listed